recombinant human erythropoietin alfa + 0.9% NaCl
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Infarction, Middle Cerebral Artery
Conditions
Infarction, Middle Cerebral Artery, Middle Cerebral Artery Stroke, Stroke, Acute
Trial Timeline
Jan 1, 2003 → Jun 1, 2008
NCT ID
NCT00604630About recombinant human erythropoietin alfa + 0.9% NaCl
recombinant human erythropoietin alfa + 0.9% NaCl is a phase 2/3 stage product being developed by Johnson & Johnson for Infarction, Middle Cerebral Artery. The current trial status is completed. This product is registered under clinical trial identifier NCT00604630. Target conditions include Infarction, Middle Cerebral Artery, Middle Cerebral Artery Stroke, Stroke, Acute.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00604630 | Phase 2/3 | Completed |
Competing Products
20 competing products in Infarction, Middle Cerebral Artery